Уважаемые пользователи!

Данный сайт содержит информацию для людей с медицинским образованием и специалистов здравоохранения.
Входя на сайт, Вы подтверждаете свое согласие с Условиями использования и Политикой конфиденциальности.



Dear visitor!
This site contains medical information for healthcare professionals.
You can go further, if you agree with Terms and Conditions and Privacy Policy on this site.

Secondary acquired nasolacrimal duct obstruction after radioiodine therapy

Cover Page
Open Access Open Access
Restricted Access Subscription Access

Abstract


Secondary acquired nasolacrimal duct obstruction after radioiodine therapy is a comparatively rare complication but it requires treatment at an early stage. The symptoms of secondary acquired nasolacrimal duct obstruction are tearing, eye redness, discharge at ocular surface, a mass growing at lacrimal sac site. The considered complication occurs after radioiodine therapy in dose of 150 mCi, the rate of occurrence is dose-dependent. There are no clinical guidelines for preventing this complication but there are reports of nasolacrimal duct preventive intubation and those about developing new drug agents that block an action of the protein that uptakes iodine in the nasolacrimal duct mucosa. For diagnosing, special diagnostic procedures and an ophthalmologist consultation are required. For the correction of this complication, conservative treatment (with low efficacy) and special surgical treatment are used, including nasolacrimal duct recanalization with different techniques and anastomosis between nasolacrimal duct and nasal cavity formation. In cases of early patient encounter, it is possible to use more functional and less invasive surgical techniques, in cases of late encounter, more invasive surgical techniques are used.


Vasily D. Yartsev

Scientific Research Institute of Eye Diseases

Author for correspondence.
Email: v.yartsev@niigb.ru
ORCID iD: 0000-0003-2990-8111
SPIN-code: 4151-4946

Russian Federation, 119021, Moscow, Rossolimo st., 11a

MD, PhD

Eugenia L. Atkova

Scientific Research Institute of Eye Diseases

Email: evg.atkova@mail.ru
ORCID iD: 0000-0001-9875-6217
SPIN-code: 1186-4060

Russian Federation, 119021, Moscow, Rossolimo st., 11a

MD, PhD

  1. Румянцев П.О., Коренев С.В. История появления терапии радиоактивным йодом. // Клиническая и экспериментальная тиреоидология. — 2015. — Т. 11. — № 4. — С. 51-55. [Rumiantsev PO, Korenev SV. The history of radioiodine therapy beginnings. Clinical and Experimental Thyroidology. 2015;11(4):51-55. (In Russ.)]. doi: https://doi.org/10.14341/ket2015451-55
  2. Seidlin SM, Rossman I, et al. Radioiodine therapy of metastases from carcinoma of the thyroid; a 6-year progress report. J Clin Endocrinol Metab. 1949;9(11):1122-1137, Il lust. doi: https://doi.org/10.1210/jcem-9-11-1122
  3. Lee SL. Complications of radioactive iodine treatment of thyroid carcinoma. J Natl Compr Canc Netw. 2010;8(11):1277-1287. doi: https://doi.org/10.6004/jnccn.2010.0094
  4. Van nostrand D. The benefits and risks of i-131 therapy in patients with well-differentiated thyroid cancer. Thyroid. 2009;19(12):1381-1391. doi: https://doi.org/10.1089/thy.2009.1611
  5. Solans R, Bosch JA, Galofre P, et al. Salivary and lacrimal Gland dysfunction (Sicca Syndrome) after radioiodine therapy. J Nucl Med. 2001;42(5):738-743.
  6. Alexander C, Bader JB, Schaefer A, et al. Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. J Nucl Med. 1998;39(9):1551-1554.
  7. Garreis F, Gottschalt M, Paulsen FP. Antimicrobial peptides as a major part of the innate immune defense at the ocular surface. Dev Ophthalmol. 2010;45:16-22. doi: https://doi.org/10.1159/000315016
  8. Leder O. The significance of extrathyroidal radioactive iodine accumulation and secretion in clinical pathology. Histochemistry. 1982;74(4):585-588. doi: https://doi.org/10.1007/bf00496673
  9. Morgenstern KE, Vadysirisack DD, Zhang Z, et al. Expression of sodium iodide symporter in the lacrimal drainage system: implication for the mechanism underlying nasolacrimal duct obstruction in I131-treated patients. Ophthalmic Plast Reconstr Surg. 2005;21(5):337-344. doi: https://doi.org/10.1097/01.iop.0000179369.75569.a8
  10. Sakahara H, Yamashita S, Suzuki K, et al. Visualization of nasolacrimal drainage system after radioiodine therapy in patients with thyroid cancer. Ann Nucl Med. 2007;21(9):525-527. doi: https://doi.org/10.1007/s12149-007-0056-5
  11. Yuoness S, Rachinsky I, Driedger AA, Belhocine TZ. Differentiated thyroid cancer with epiphora: detection of nasolacrimal duct obstruction on I-131 Spect/Ct. Clin Nucl Med. 2011;36(12):1149-1152. Doi: Https://doi.org/10.1097/Rlu.0b013e3182336016
  12. Ali MJ, Vyakaranam AR, Rao JE, et al. Iodine-131 therapy and lacrimal drainage system toxicity: nasal localization studies using whole body nuclear scintigraphy and SPECT-CT. Ophthalmic Plast Reconstr Surg. 2017;33(1):13-16. doi: https://doi.org/10.1097/IOP.0000000000000603
  13. Kloos RT, Duvuuri V, Jhiang SM, et al. Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma. J Clin Endocrinol Metab. 2002;87(12):5817-5820. doi: https://doi.org/10.1210/jc.2002-020210
  14. Shepler TR, Sherman SI, Faustina MM, et al. Nasolacrimal duct obstruction associated with radioactive iodine therapy for thyroid carcinoma. Ophthalmic Plast Reconstr Surg. 2003;19(6):479-481. doi: https://doi.org/10.1097/01.IOP.0000092802.75899.F8
  15. Al-Qahtani KH, Al Asiri M, Tunio MA, et al. Nasolacrimal duct obstruction following radioactive iodine 131 therapy in differentiated thyroid cancers: review of 19 cases. Clin Ophthalmol. 2014;8:2479-2484. doi: https://doi.org/10.2147/OPTH.S71708
  16. Brockmann H, Wilhelm K, Joe A, et al. Nasolacrimal drainage obstruction after radioiodine therapy: case report and a review of the literature. Clin Nucl Med. 2005;30(8):543-545. doi: https://doi.org/10.1097/01.rlu.0000170013.84378.2a
  17. Burns JA, Morgenstern KE, Cahill KV, et al. Nasolacrimal obstruction secondary to I131 therapy. Ophthalmic Plast Reconstr Surg. 2004;20(2):126-129. doi: https://doi.org/10.1097/01.iop.0000117340.41849.81
  18. Fonseca FL, Lunardelli P, Matayoshi S. Lacrimal drainage system obstruction associated to radioactive iodine therapy for thyroid carcinoma. Arq Bras Oftalmol. 2012;75(2):97-100.
  19. Sun GE, Hatipoglu B. Epiphora after radioactive iodine ablation for thyroid cancer. Thyroid. 2013;23(2):243-245. doi: https://doi.org/10.1089/thy.2011.0186
  20. Ali MJ. Iodine-131 therapy and nasolacrimal duct obstructions: what we know and what we need to know. Ophthalmic Plast Reconstr Surg. 2016;32(4):243-248. doi: https://doi.org/10.1097/IOP.0000000000000647
  21. Fard-Esfahani A, Farzanefar S, Fallahi B, et al. Nasolacrimal duct obstruction as a complication of iodine-131 therapy in patients with thyroid cancer. Nucl Med Commun. 2012;33(10):1077-1080. doi: https://doi.org/10.1097/MNM.0b013e3283570fb8
  22. Sagili S, Selva D, Malhotra R. Lacrimal scintigraphy: interpretation more art than science. Orbit. 2012;31(2):77-85. doi: https://doi.org/10.3109/01676830.2011.648797
  23. da Fonseca FL, Yamanaka PK, Kato JM, Matayoshi S. Lacrimal system obstruction after radioiodine therapy in differentiated thyroid carcinomas: a prospective comparative study. Thyroid. 2016;26(12):1761-1767. doi: https://doi.org/10.1089/thy.2015.0657
  24. Song H, Jeong J, Ju Koh M. Epiphora after radioactive iodine therapy in a low-risk patient. Clin Nucl Med. 2015;40(6):536-537. doi: https://doi.org/10.1097/RLU.0000000000000717
  25. Атькова Е.Л., Федоров А.А., Резникова Л.В., и др. Пятилетний опыт использования цитологического метода в дакриологии. // Вестник офтальмологии. — 2013. — Т. 129. — № 5. — С. 104-113. [At’kova EL, Fedorov AA, Reznikova LV, et al. Five-year application experience of cytological method in dacryological practice. Annals of ophtalmology. 2013;129(5):104-113. (In Russ.)].
  26. Choontanom R. Probing and syringing with 3% solution of NaCl and/or 0.2 mg/ml mitomycin-C in nasolacrimal duct obstruction patients. J Med Assoc Thai. 2010;93(Suppl 6):S197-S202.
  27. Rumelt S. Primary treatment of nasolacrimal duct obstruction. J AAPOS. 2009;13(4):426; author reply 426-427. doi: https://doi.org/10.1016/j.jaapos.2009.04.003
  28. Атькова Е.Л., Федоров А.А., Ярцев В.Д., Роот А.О. Разработка оптимального способа проведения баллонной дакрио пластики. // Вестник офтальмологии. — 2015. — Т. 131. — № 2. — С. 99-104. [At’kova EL, Fedorov AA, Yartsev VD, Root AO. Developing the optimal protocol for balloon dacryoplasty. Annals of ophtalmology. 2015;131(2):99-104. (In Russ.)]. doi: https://doi.org/10.17116/oftalma2015131299-104
  29. Атькова Е.Л., Ярцев В.Д., Краховецкий Н.Н., Роот А.О. Малоинвазивные вмешательства при дакриостенозе: современные тенденции. // Вестник офтальмологии. — 2014. — Т. 130. — № 6. — С. 89-97. [At’kova EL, Iartsev VD, Krakhovetskii NN, Root AO. Minimally invasive surgery for dacryostenosis: modern trends. Annals of ophtalmology. 2014;130(6):89-97. (In Russ.)].
  30. Белоглазов В.Г. Альтернативные варианты восстановления проходимости слезоотводящих путей. // Вестник офтальмологии. — 2006. — Т. 122. — № 1. — С. 8-12. [Beloglazov VG. Alternatives to recovery of lacrimal duct patency. Annals of ophtalmology. 2006;122(1):8-12. (In Russ.)].
  31. Sweeney AR, Davis GE, Chang SH, Amadi AJ. Outcomes of endoscopic dacryocystorhinostomy in secondary acquired nasolacrimal duct obstruction: a case-control study. Ophthalmic Plast Reconstr Surg. 2018;34(1):20-25. doi: https://doi.org/10.1097/IOP.0000000000000841
  32. Juniat VAR, Rajak S. The use of prophylactic Nunchaku stents to reduce the risk of nasolacrimal duct obstruction in patients with midfacial tumours undergoing radiotherapy. Orbit. 2017;36(5):298-300. doi: https://doi.org/10.1080/01676830.2017.1337182

Supplementary files

There are no supplementary files to display.

Views

Abstract - 66

PDF (Russian) - 9

Remote (Russian) - 2

PlumX


Copyright (c) 2019 Yartsev V.D., Atkova E.L.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.